BR112022015457A2 - Formulação de comprimido, método para tratar insuficiência cardíaca, uso de uma formulação de comprimido, e, processo para fazer uma formulação de comprimido - Google Patents

Formulação de comprimido, método para tratar insuficiência cardíaca, uso de uma formulação de comprimido, e, processo para fazer uma formulação de comprimido

Info

Publication number
BR112022015457A2
BR112022015457A2 BR112022015457A BR112022015457A BR112022015457A2 BR 112022015457 A2 BR112022015457 A2 BR 112022015457A2 BR 112022015457 A BR112022015457 A BR 112022015457A BR 112022015457 A BR112022015457 A BR 112022015457A BR 112022015457 A2 BR112022015457 A2 BR 112022015457A2
Authority
BR
Brazil
Prior art keywords
formulation
pill
making
heart failure
tablet
Prior art date
Application number
BR112022015457A
Other languages
English (en)
Portuguese (pt)
Inventor
Bi Mingda
Kiang Yuan-Hon
Lou Hao
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of BR112022015457A2 publication Critical patent/BR112022015457A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/2853Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893Tablet coating processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
BR112022015457A 2020-02-10 2021-02-10 Formulação de comprimido, método para tratar insuficiência cardíaca, uso de uma formulação de comprimido, e, processo para fazer uma formulação de comprimido BR112022015457A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062972506P 2020-02-10 2020-02-10
PCT/US2021/017429 WO2021163172A1 (en) 2020-02-10 2021-02-10 Omecamtiv mecarbil tablet

Publications (1)

Publication Number Publication Date
BR112022015457A2 true BR112022015457A2 (pt) 2022-10-04

Family

ID=74858801

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022015457A BR112022015457A2 (pt) 2020-02-10 2021-02-10 Formulação de comprimido, método para tratar insuficiência cardíaca, uso de uma formulação de comprimido, e, processo para fazer uma formulação de comprimido

Country Status (9)

Country Link
US (1) US20230090391A1 (https=)
EP (1) EP4103159A1 (https=)
JP (1) JP7696353B2 (https=)
CN (1) CN115279349A (https=)
AU (1) AU2021221106A1 (https=)
BR (1) BR112022015457A2 (https=)
CA (1) CA3168513A1 (https=)
IL (1) IL295490A (https=)
WO (1) WO2021163172A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2522579T3 (es) 2004-06-17 2014-11-17 Cytokinetics, Inc. Compuestos, composiciones y métodos
SG11201507258PA (en) 2013-03-14 2015-10-29 Amgen Inc Heterocyclic compounds and their uses
DK3645002T3 (da) 2017-06-30 2024-12-16 Amgen Inc Fremgangsmåder til behandling af hjertesvigt med hjerte-sarkomer-aktivatorer
AU2018294254C1 (en) 2017-06-30 2022-10-13 Amgen Inc. Synthesis of omecamtiv mecarbil
PT3594199T (pt) 2018-07-09 2020-09-04 Amgen Inc 2-fluoro-3-nitrotolueno cristalino e processo para a sua preparação
MA53226A (fr) 2018-08-17 2021-11-24 Amgen Inc Sel et formes cristallines d'omecamtiv mecarbil
WO2020131574A1 (en) 2018-12-18 2020-06-25 Amgen Inc. Method of reducing aromatic nitro compounds
DK4243825T3 (da) 2020-11-12 2025-12-01 Amgen Inc Omecamtiv mecarbil til behandling af hjerteinsattsvigt hos udvalgte patientgrupper
IL305751A (en) 2021-03-10 2023-11-01 Amgen Inc SYNTHESIS OF OMECAMTIV MECARBIL
US20250161298A1 (en) * 2022-02-22 2025-05-22 Yale University Methods of treating, ameliorating, or preventing heart failure, and methods of promoting heart muscle growth
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2419007T3 (es) * 2005-12-15 2013-08-19 Cytokinetics, Inc. Ciertas entidades químicas, composiciones y procedimientos
SG11201507258PA (en) * 2013-03-14 2015-10-29 Amgen Inc Heterocyclic compounds and their uses
US9895308B2 (en) * 2013-03-14 2018-02-20 Amgen Inc. Heterocyclic compounds and their uses
DK3645002T3 (da) * 2017-06-30 2024-12-16 Amgen Inc Fremgangsmåder til behandling af hjertesvigt med hjerte-sarkomer-aktivatorer

Also Published As

Publication number Publication date
EP4103159A1 (en) 2022-12-21
US20230090391A1 (en) 2023-03-23
JP2023513249A (ja) 2023-03-30
IL295490A (en) 2022-10-01
CN115279349A (zh) 2022-11-01
AU2021221106A1 (en) 2022-09-22
JP7696353B2 (ja) 2025-06-20
WO2021163172A1 (en) 2021-08-19
CA3168513A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
BR112022015457A2 (pt) Formulação de comprimido, método para tratar insuficiência cardíaca, uso de uma formulação de comprimido, e, processo para fazer uma formulação de comprimido
EP4461355A3 (en) Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use
WO2020051207A3 (en) Aryl hydrocarbon receptor antagonists and methods of use
BR112018011376A2 (pt) composição farmacêutica que compreende um inibi-dor de urat1 potente
GEAP202316333A (en) Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use
MX2020012967A (es) Combinacion farmaceutica que contiene activador de glucosacinasa y activador del receptor ppar, composicion, preparacion del compuesto, metodo de preparacion para el mismo y usos del mismo.
BRPI0822162B8 (pt) composição farmacêutica para tratamento tópico de doença das unhas ou leito ungueal
BR112018073298A2 (pt) cápsula, suspensão de cápsula, mistura, uso das cápsulas e método para reduzir a nitrificação
BR112018006039A2 (pt) terapia adjuvante com 25-hidroxivitamina d e artigos para a mesma
BR112012026953A8 (pt) Composto, uso de um composto, composição farmacêutica, e processo para preparar uma composição farmacêutica
BRPI0512583B8 (pt) composições e métodos de produção das mesmas, de liberação de agente ativo para e através do tecido da epiderme de pessoa ou animal e de tratamento de paciente que sofre de onicomicose, de psoríase de unha e de infecções
AR064875A1 (es) Composiciones de tableta en tableta
BR112017017078A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para prevenir, gerenciar, tratar ou amenizar uma doença.
BRPI0704238A (pt) preventivo da doença de coccidiose e clostrìdica e/ou terapia para a doença de coccidiose e clostridica
BR112017017448A2 (pt) métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho
BR112017008993A2 (pt) métodos e composições especificamente para o tratamento de transtorno de déficit de atenção
BR112016015763B8 (pt) preparação farmacêutica incluindo composto de ácido piridilaminocético, e, uso da mesma
BR112018074660A2 (pt) composição para os cuidados pessoais, método para a redução do aparecimento de linhas finas, rugas, poros e/ou manchas de imperfeição e utilização de uma composição
BR112022022452A2 (pt) Inibidores de il4i1 e métodos de uso
BR112021017878A2 (pt) Carbonato de magnésio com superfície reagida, sistema de liberação, formulação de cuidados domiciliares, métodos para preparar um carbonato de magnésio com superfície reagida e para preparar um sistema de liberação, e, uso de um carbonato de magnésio com superfície reagida e de um sistema de liberação
BR112017006406A2 (pt) composições e métodos para o tratamento e profilaxia de infecções de sítio cirúrgico
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
BR112023000654A2 (pt) Composto de pirazolopirimidina usado como inibidor de atr quinase
PY1903392A (es) Composiciones oftálmicas de compuestos de bencimidazol para uso único diario
MX2022005749A (es) Inhibidores de egfr alostericos y metodos de uso de los mismos.

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]